Literature DB >> 20485640

Precursor lesions of pancreatic cancer.

Suguru Yonezawa1, Michiyo Higashi, Norishige Yamada, Masamichi Goto.   

Abstract

This review article describes morphological aspects, gene abnormalities, and mucin expression profiles in precursor lesions such as pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), and mucinous cystic neoplasm (MCN) of the pancreas, as well as their relation to pancreatic ductal adenocarcinoma (PDAC). The gene abnormalities in precursors of PDAC are summarized as follows: (1) KRAS mutation and p16/CDKN2A inactivation are early events whose frequencies increase with the dysplasia grade in both PanIN and IPMN; (2) TP53 mutation and SMAD4/DPC4 inactivation are late events observed in PanIN3 or carcinomatous change of IPMN in both PanIN and IPMN, although the frequency of the TP53 mutation is lower in IPMN than in PDAC; and (3) also in MCN, KRAS mutation is an early event whose frequency increases with the dysplasia grade, whereas TP53 mutation and SMAD4/DPC4 inactivation are evident only in the carcinoma. The mucin expression profiles in precursors of PDAC are summarized as follows: (1) MUC1 expression increases with the PanIN grade, and is high in PDAC; (2) the expression pattern of MUC2 differs markedly between the major subtypes of IPMN with different malignancy potentials (i.e., IPMN-intestinal type with MUC2+ expression and IPMN-gastric type with MUC2- expression); (3) MUC2 is not expressed in any grade of PanINs, which is useful for differentiating PanIN from intestinal-type IPMN; (4) de novo expression of MUC4, which appears to increase with the dysplasia grade; and (5) high de novo expression of MUC5AC in all grades of PanINs, all types of IPMN, MCN, and PDAC.

Entities:  

Keywords:  Gene analysis; Intraductal papillary mucinous neoplasm; Mucin expression; Mucinous cystic neoplasm; Pancreatic ductal adenocarcinoma; Pancreatic intraepithelial neoplasia

Year:  2008        PMID: 20485640      PMCID: PMC2871636          DOI: 10.5009/gnl.2008.2.3.137

Source DB:  PubMed          Journal:  Gut Liver        ISSN: 1976-2283            Impact factor:   4.519


  114 in total

1.  Molecular cloning of human intestinal mucin (MUC2) cDNA. Identification of the amino terminus and overall sequence similarity to prepro-von Willebrand factor.

Authors:  J R Gum; J W Hicks; N W Toribara; B Siddiki; Y S Kim
Journal:  J Biol Chem       Date:  1994-01-28       Impact factor: 5.157

2.  Intraductal oncocytic papillary neoplasms of the pancreas.

Authors:  N V Adsay; C F Adair; C S Heffess; D S Klimstra
Journal:  Am J Surg Pathol       Date:  1996-08       Impact factor: 6.394

3.  Overexpression of p53 protein in adenocarcinoma of the pancreas.

Authors:  J A DiGiuseppe; R H Hruban; S N Goodman; M Polak; F M van den Berg; D C Allison; J L Cameron; G J Offerhaus
Journal:  Am J Clin Pathol       Date:  1994-06       Impact factor: 2.493

4.  Immunohistochemical study of mucin carbohydrates and core proteins in hepatolithiasis and cholangiocarcinoma.

Authors:  K Yamashita; S Yonezawa; S Tanaka; H Shirahama; K Sakoda; K Imai; P X Xing; I F McKenzie; J Hilkens; Y S Kim
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

5.  Frequent c-Ki-ras oncogene activation in mucous cell hyperplasias of pancreas suffering from chronic inflammation.

Authors:  A Yanagisawa; K Ohtake; K Ohashi; M Hori; T Kitagawa; H Sugano; Y Kato
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

6.  Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.

Authors:  M Osako; S Yonezawa; B Siddiki; J Huang; J J Ho; Y S Kim; E Sato
Journal:  Cancer       Date:  1993-04-01       Impact factor: 6.860

7.  DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.

Authors:  S A Hahn; M Schutte; A T Hoque; C A Moskaluk; L T da Costa; E Rozenblum; C L Weinstein; A Fischer; C J Yeo; R H Hruban; S E Kern
Journal:  Science       Date:  1996-01-19       Impact factor: 47.728

8.  Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma.

Authors:  M P Buisine; A Janin; V Maunoury; J P Audié; M P Delescaut; M C Copin; J F Colombel; P Degand; J P Aubert; N Porchet
Journal:  Gastroenterology       Date:  1996-01       Impact factor: 22.682

9.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

Authors:  N S Pellegata; F Sessa; B Renault; M Bonato; B E Leone; E Solcia; G N Ranzani
Journal:  Cancer Res       Date:  1994-03-15       Impact factor: 12.701

10.  Immunohistochemical evaluation of HER-2/neu expression in pancreatic adenocarcinoma and pancreatic intraepithelial neoplasms.

Authors:  J D Day; J A Digiuseppe; C Yeo; M Lai-Goldman; S M Anderson; S N Goodman; S E Kern; R H Hruban
Journal:  Hum Pathol       Date:  1996-02       Impact factor: 3.466

View more
  32 in total

1.  Genomic sequencing of key genes in mouse pancreatic cancer cells.

Authors:  Y Wang; Y Zhang; J Yang; X Ni; S Liu; Z Li; S E Hodges; W E Fisher; F C Brunicardi; R A Gibbs; M-C Gingras; M Li
Journal:  Curr Mol Med       Date:  2012-03       Impact factor: 2.222

Review 2.  Pathological features and diagnosis of intraductal papillary mucinous neoplasm of the pancreas.

Authors:  Víctor M Castellano-Megías; Carolina Ibarrola-de Andrés; Guadalupe López-Alonso; Francisco Colina-Ruizdelgado
Journal:  World J Gastrointest Oncol       Date:  2014-09-15

3.  Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma.

Authors:  Yoshiaki Kamikawa; Yuji Kanmura; Tomofumi Hamada; Norishige Yamada; Muzafar A Macha; Surinder K Batra; Michiyo Higashi; Suguru Yonezawa; Kazumasa Sugihara
Journal:  Int J Clin Oncol       Date:  2014-06-10       Impact factor: 3.402

Review 4.  Mucins in pancreatic cancer and its microenvironment.

Authors:  Sukhwinder Kaur; Sushil Kumar; Navneet Momi; Aaron R Sasson; Surinder K Batra
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-16       Impact factor: 46.802

Review 5.  Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines.

Authors:  Jason Lohmueller; Olivera J Finn
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

6.  Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Authors:  Helen Court; Marc Amoyel; Michael Hackman; Kyoung Eun Lee; Ruliang Xu; George Miller; Dafna Bar-Sagi; Erika A Bach; Martin O Bergö; Mark R Philips
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

7.  Well-differentiated pancreatic ductal adenocarcinomas measuring ≤ 1 cm exhibit early features of tumor progression: a report of five lesions and a comparative study with advanced lesions.

Authors:  Sadanobu Izumi; Satoko Nakamura; Shohei Mano; Yuji Onoda
Journal:  Surg Today       Date:  2013-12-03       Impact factor: 2.549

Review 8.  The National Cancer Institute's PREVENT Cancer Preclinical Drug Development Program: overview, current projects, animal models, agent development strategies, and molecular targets.

Authors:  Robert H Shoemaker; Chen S Suen; Cathy A Holmes; Judith R Fay; Vernon E Steele
Journal:  Semin Oncol       Date:  2015-09-08       Impact factor: 4.929

Review 9.  Selection criteria in resectable pancreatic cancer: a biological and morphological approach.

Authors:  Domenico Tamburrino; Stefano Partelli; Stefano Crippa; Alberto Manzoni; Angela Maurizi; Massimo Falconi
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 10.  Peroxisome proliferator activated receptors at the crossroad of obesity, diabetes, and pancreatic cancer.

Authors:  Simone Polvani; Mirko Tarocchi; Sara Tempesti; Lapo Bencini; Andrea Galli
Journal:  World J Gastroenterol       Date:  2016-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.